Accelerated atherosclerosis in systemic lupus erythematosus: Perspectives towards decreasing cardiovascular morbidity and mortality

Lupus

Volumn 18, Issue 5, 2009, Pages 383-386

  Escárcega, Ricardo Orlando ^a   Garcia Carrasco, M ^b   Jara, L J ^c   Cervera, R ^d  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SMOKING CESSATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

ASPIRIN; AZETIDINES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK;

EID: 63749120002     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308101435     Document Type: Editorial

References (22)

1. Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006; 6: 48-53.
2. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683-686.
3. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
4. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167-175.
5. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
6. García-Carrasco M, Escárcega RO, Pérez-Terrón J, et al. Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease. Lupus 2007; 16: 298-301.
7. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389-397.
8. Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.
9. Brown GB, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in Ezetimibe. N Engl J Med 2008; 358: 1504-1506.
10. Jackevicius CA, Tu JV, Ross JS, Ko D, Krumholz H. Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358: 1819-1828.
11. Tinetti ME. Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 2008; 358: 2728-2732.
12. Petri M, Kiani A, Post W, Madger L. Lupus Atherosclerosis prevention study (LAPS): A randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum; 54(Suppl.): S5-S20.
13. Lawman S, Mauri C, Jury EC, Cook HT, Ehrestein MR. Atorvastatin Inhibit autoreactive B cell activation and delays lupus development in new Zealand black/white F1 mice. J Immunol 2004; 173: 7641-7646.
14. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients and preventive practices. Medicine 1992; 71: 291-302.
15. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus (The Toronto risk factor study). Arthritis Rheum 2003; 48: 3159-3167.
16. Petri M, Rubenhoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
17. Van den Brandhof WE, Haks K, Schouten EG, Verhoef P. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001; 157: 403-409.
18. Sherer Y, Tenembaum A, Praprotnik S, et al. Coronary disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 2001; 95: 20-24.
19. Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99-106.
20. Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS study). Autoimmun Rev 2008; DOI: 10.1016/j.autrev.2008.10.002.
21. Eidelman RS, Hebert PR, Weisman SE, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-2010.
22. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005; 352: 1293-1304.